| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/01/2002 | CA2435775A1 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof |
| 08/01/2002 | CA2435653A1 Anti-cancer 2,3-dihydro-1h-pyrrolo[3,2-f]quinoline complexes of cobalt and chromium |
| 08/01/2002 | CA2435647A1 Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and use |
| 08/01/2002 | CA2435633A1 Antiangiogenic compounds and an assay for inhibitors of cell invasion |
| 08/01/2002 | CA2435573A1 Alkyl aryl polyether alcohol polymers for improvement of nasal breathing |
| 08/01/2002 | CA2435566A1 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| 08/01/2002 | CA2435562A1 Carotenoids as anti-hypertension agents |
| 08/01/2002 | CA2435418A1 Use of neurotoxic substances in producing a medicament for treating joint pains |
| 08/01/2002 | CA2435415A1 Microparticles of biodegradable polymer encapsulating a biologically active substance |
| 08/01/2002 | CA2435410A1 Systemic formulations containing beta-carotene and derivatives thereof |
| 08/01/2002 | CA2435409A1 Novel cannabimimetic ligands |
| 08/01/2002 | CA2435124A1 Formulation of boronic acid compounds |
| 08/01/2002 | CA2435047A1 Constitutively desensitized g protein-coupled receptors |
| 08/01/2002 | CA2435038A1 Inhibition of erk to reduce or prevent tolerance to and dependence on opioid analgesics |
| 08/01/2002 | CA2434929A1 Method of treatment of type i diabetes |
| 08/01/2002 | CA2434765A1 Degradation-resistant glucocorticosteroid formulations |
| 08/01/2002 | CA2434584A1 Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones |
| 08/01/2002 | CA2434558A1 Imidazolyl derivatives as corticotropin releasing factor inhibitors |
| 08/01/2002 | CA2434504A1 Combinations of sterol absorption inhibitor(s) with blood modifiers for treating vascular conditions |
| 08/01/2002 | CA2434488A1 Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications |
| 08/01/2002 | CA2434436A1 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 08/01/2002 | CA2434430A1 The use of substituted azetidinone compounds for the treatment of sitosterolemia |
| 08/01/2002 | CA2434226A1 Process for preparing non-hygroscopic sodium valproate composition |
| 08/01/2002 | CA2434085A1 Cyclin dependent kinase inhibiting purine derivatives |
| 08/01/2002 | CA2434052A1 Use of rhein for preparing a medicine for treating a high level of il-1 |
| 08/01/2002 | CA2434050A1 Herbal composition for angina pectoris, method to prepare same and uses thereof |
| 08/01/2002 | CA2434033A1 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| 08/01/2002 | CA2433838A1 Process for preparing particles |
| 08/01/2002 | CA2433762A1 Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy |
| 08/01/2002 | CA2433530A1 New film coating |
| 08/01/2002 | CA2433025A1 Substituted piperidines/piperazines as melanocortin receptor agonists |
| 08/01/2002 | CA2432988A1 Melanocortin receptor agonists |
| 08/01/2002 | CA2432985A1 Piperazine- and piperidine-derivatives as melanocortin receptor agonists |
| 08/01/2002 | CA2432276A1 Regulation of cell growth by muc1 |
| 08/01/2002 | CA2432122A1 Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands |
| 08/01/2002 | CA2431996A1 Melanocortin receptor agonists |
| 08/01/2002 | CA2431970A1 Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonists and antagonists |
| 08/01/2002 | CA2431904A1 (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
| 08/01/2002 | CA2431313A1 Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators |
| 08/01/2002 | CA2431177A1 Trem-1 splice variant for use in modifying immune responses |
| 08/01/2002 | CA2429353A1 Lfa-1 antagonist compounds |
| 08/01/2002 | CA2429034A1 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and uses thereof |
| 08/01/2002 | CA2428425A1 Method of treating hematologic tumors and cancers |
| 08/01/2002 | CA2427061A1 Methods and compositions for the identification and treatment of neurodegenerative disorders |
| 08/01/2002 | CA2424402A1 Antimicrobial quinolone derivatives and use of the same to treat bacterial infections |
| 08/01/2002 | CA2421583A1 Oxazolidinones having a benzannulated 6-or 7-membered heterocycle as antibacterial agents |
| 08/01/2002 | CA2333844A1 Bio-energy muscle relaxants |
| 07/31/2002 | EP1227152A1 Bacterial strain and genome of bifidobacterium |
| 07/31/2002 | EP1227103A2 Ring-expanded nucleosides and nucleotides |
| 07/31/2002 | EP1227099A1 Fused Pyrazolyl compounds |
| 07/31/2002 | EP1227096A1 4-oxoquinolizine antimicrobials having 2-pyridone skeletons as the partial structure |
| 07/31/2002 | EP1227095A2 A process for the purification of (S)-4-((3-(dimethylamino)ethyl)-1H-indol-5yl)-methyl)-2-oxazolidinone |
| 07/31/2002 | EP1227093A2 Beta-lactams useful for preparation of taxanes having furyl or thienyl substituted side-chain |
| 07/31/2002 | EP1227092A2 Isonitrile intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties |
| 07/31/2002 | EP1227091A2 Formamide intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties |
| 07/31/2002 | EP1227090A1 Amine derivatives |
| 07/31/2002 | EP1227088A1 Crystalline base of citalopram and hydrochoride or hydrobromide salt thereof |
| 07/31/2002 | EP1227085A1 Process for producing optically active naphthalene derivative and optical resolver therefor |
| 07/31/2002 | EP1227084A1 Drug discharge pump inhibitors |
| 07/31/2002 | EP1227083A1 3-AMINOPIPERIDINE DERIVATIVES AS INTEGRIN $g(a)v$g(b)3 ANTAGONISTS |
| 07/31/2002 | EP1227082A1 Process for producing carotenoid emulsion |
| 07/31/2002 | EP1227081A1 Process for the preparation of oxyiminoalkanoic acid derivatives |
| 07/31/2002 | EP1226864A1 A stable water-in-oil-in-water multiple emulsion system by hydrodynamic dual stabilization and a method for preparation thereof |
| 07/31/2002 | EP1226831A1 Aqueous pharmaceutical solutions with trisubstituted glycyrrhizic acid salts |
| 07/31/2002 | EP1226830A2 Combination therapy involving a sodium-hydrogen exchanger type 1 or NHE-1 inhibitor for use in treatment of ischemia |
| 07/31/2002 | EP1226827A1 An anti-oedema composition,in particular for pharmaceutical use. |
| 07/31/2002 | EP1226826A1 Remedies |
| 07/31/2002 | EP1226825A1 Erection insufficiency remedies |
| 07/31/2002 | EP1226824A1 Use of thalidomide for the treatment of hepatocellular carcinoma |
| 07/31/2002 | EP1226823A2 Method of treating certain cancers using an estrogen agonist/antagonist |
| 07/31/2002 | EP1226822A2 Promoter for production of nitric oxide or nitric oxide synthase, and cosmetic or pharmaceutical composition comprising the same |
| 07/31/2002 | EP1226821A2 The use of 2,3-alkylcarbonyloxybenzoic acid in treating adult respiratory distress syndrome |
| 07/31/2002 | EP1226820A1 Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders |
| 07/31/2002 | EP1226819A1 Inhibitor for 20-hete-yielding enzyme |
| 07/31/2002 | EP1226817A2 Anti-germ attachment composition |
| 07/31/2002 | EP1226438A1 Composite nanospheres and their conjugates with biomolecules |
| 07/31/2002 | EP1226435A1 Axor35, a g-protein coupled receptor |
| 07/31/2002 | EP1226279A1 Modulation of neuroendocrine differentiation by protein 25.1 |
| 07/31/2002 | EP1226263A1 Invasive bacterial vectors for expressing alphavirus replicons |
| 07/31/2002 | EP1226248A1 Cloning, expression and characterisation of a gene expressed in tumour cells and involved in the regulation of the immune response |
| 07/31/2002 | EP1226242A1 Human cub-domain-containing protein and gene encoding the same |
| 07/31/2002 | EP1226212A1 Polymeric composition for solubilizing poorly water soluble drugs and process for the preparation thereof |
| 07/31/2002 | EP1226177A2 Anti-prostate stem cell antigen (psca) antibody compositions and methods of use |
| 07/31/2002 | EP1226170A2 Human proteins and polynucleotides encoding the same |
| 07/31/2002 | EP1226159A1 Substituted dipeptides having nos inhibiting activity |
| 07/31/2002 | EP1226155A2 18-nor-steroids as selectively active estrogens |
| 07/31/2002 | EP1226154A1 Estradiol conjugates and uses thereof |
| 07/31/2002 | EP1226151A2 Gene expression directed by a super-psa promoter |
| 07/31/2002 | EP1226150A1 Tadg-15: an extracellular serine protease overexpressed in carcinomas |
| 07/31/2002 | EP1226148A2 Novel oligosaccharides, preparation method and pharmaceutical compositions containing same |
| 07/31/2002 | EP1226146A2 Quinoline and naphthyridine carboxylic acid antibacterials |
| 07/31/2002 | EP1226144A1 Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase |
| 07/31/2002 | EP1226143A2 Imidazopyridine derivatives used as phosphodiesterase vii inhibitors |
| 07/31/2002 | EP1226141A1 Heterocyclic substituted pyrazolones |
| 07/31/2002 | EP1226140A1 Novel indole compounds |
| 07/31/2002 | EP1226139A2 Cyclized amide derivatives for treating or preventing neuronal damage |
| 07/31/2002 | EP1226138A1 Fab i inhibitors |
| 07/31/2002 | EP1226137A1 Phenyl- and pyridyl-tetrahydro-pyridines having tnf inhibiting activity |
| 07/31/2002 | EP1226136A2 Tyrosine kinase inhibitors |
| 07/31/2002 | EP1226133A2 N-SUBSTITUTED 3-AMINO-2,2-DI-C-ALKYL-1,4-BUTYROLACTONES AND 1,4-THIOBUTYROLACTONES FOR USE AS PROMOTER OF $g(g)-AMINOBUTYRIC ACID ACTIVITY AND FOR TREATING NERVOUS DISORDERS AND PREPARATION METHOD |